The mechanisms involved in the progression from monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) to malignant multiple myeloma (MM) and plasma cell leukemia (PCL) are poorly understood but believed to involve the sequential acquisition of genetic hits. We performed exome and whole-genome sequencing on a series of MGUS (n ¼ 4), high-risk (HR)SMM (n ¼ 4), MM (n ¼ 26) and PCL (n ¼ 2) samples, including four cases who transformed from HR-SMM to MM, to determine the genetic factors that drive progression of disease. The pattern and number of non-synonymous mutations show that the MGUS disease stage is less genetically complex than MM, and HR-SMM is similar to presenting MM. Intraclonal heterogeneity is present at all stages and using cases of HR-SMM, which transformed to MM, we show that intraclonal heterogeneity is a typical feature of the disease. At the HR-SMM stage of disease, the majority of the genetic changes necessary to give rise to MM are already present. These data suggest that clonal progression is the key feature of transformation of HR-SMM to MM and as such the invasive clinically predominant clone typical of MM is already present at the SMM stage and would be amenable to therapeutic intervention at that stage.
INTRODUCTION
A key question in cancer biology is how a cell transforms from an essentially benign premalignant condition to a malignant invasive state. Some hints as to how this happens can come from the study of multiple myeloma (MM), which is characterized by the proliferation of abnormal plasma cells (PC) 1 that have fewer mutations than the more complex solid tumors and as such provides a good model in which to address the question of cancer progression. Current understanding of MM development is thought to involve a multistep transformation process, occurring as a consequence of the sequential acquisition of genetic hits that deregulate the behavior of a normal PC, Figure 1a . The first stage of this process is a benign premalignant condition, known as monoclonal gammopathy of undetermined significance (MGUS) that transforms to MM at a rate of 1% per annum. 2, 3 The next step of MM evolution is the development of smoldering myeloma (SMM) that shares the same morphological features as symptomatic MM, but lacks evidence of end-organ damage; 4 and progresses to MM at a rate of 10% per annum. 2 In the final stage of the transformation process, the malignant PC clone gains independence from the bone marrow (BM) microenvironment, presenting either as PC leukemia (PCL) or as extra-medullary myeloma. 5 Translocations, involving the immunoglobulin heavy-chain (IGH) locus, or hyperdiploidy are seen as primary events in myeloma that are present in 100% of cells but these alone are not sufficient to result in clinically invasive myeloma, given that they can be found in patients with MGUS and may be stable for many years. 6 Therefore, there must be additional genetic events, which contribute toward disease progression leading to the invasive stages of the disease. There is significant interest in defining these driver mutations that push the malignant clone toward more invasive behavior, as they constitute good therapeutic targets. The main approach to identifying these variables has been through comparing the genetics of samples taken from different individuals who have MGUS, SMM or MM. As a result of such studies, we have identified a number of lesions, which are known to contribute to disease progression including an increased frequency of copy number abnormalities, 7, 8 genomewide hypomethylation and gene-specific hypermethylation, 9, 10 secondary translocations (often involving MYC) 11 and altered gene expression. 12, 13 A more elegant way of accurately defining the genetic factors associated with disease progression is to study sequential samples from the same patient as they progress from one clinical stage to another, yet few such studies have done this because of the difficulty in obtaining paired samples from the same individual. The limited number of studies that have taken this approach, however, have been very informative showing that the frequency of genomic alterations, such as translocations and copy number alterations, increases with disease progression, but as a rule they are generally present during the early stages of disease. [14] [15] [16] [17] [18] Since such studies have been performed, technology has moved on and the availability of genome-wide analyses, such as massively parallel sequencing, has provided a tool that is able to deliver an unbiased genome-wide assessment of the changes present during the transition from one clinical state to another.
Understanding the biology underlying cancer progression is important for therapeutic strategies aimed at cancer control and is being studied intensively. The results of recent analyses have suggested that instead of following a linear multistep pathway through this transformation process, progression is more likely to develop via a branching evolutionary process, as first used by Darwin to explain the evolution of species. 19, 20 This model of cancer evolution requires the coexistence of multiple diverging clones, the essential substrate for evolution, and has been recently demonstrated in a number of different malignancies, including MM. [21] [22] [23] Even within such Darwinian models, it remains important to understand what drives the competition between clones in order to effectively manipulate it therapeutically. Therefore, investigating the relationship between high-risk (HR)SMM and MM in paired samples that have undergone the SMM-MM transformation provides the opportunity to define novel genetic hits that contribute to subclonal growth and survival advantage that mediates the development of end-organ damage. In this study, we have used massively parallel sequencing to study the genetic makeup of the stages of MM and in particular to investigate the genetic relationship of the transition from HR-SMM to MM.
MATERIALS AND METHODS
Samples were derived from the QUIREDEX study (NCT00480363), where HR-SMM cases were randomized to receive either therapy with lenalidomide and dexamethasone or to undergo longitudinal follow up only. HR-SMM was defined as the presence of 410% PC in the BM and a monoclonal component IgG X3 g/dl, IgA X2 g/dl or Bence Jones proteinuria X1 g/24 h together with the absence of CRAB (calcium increase, renal insufficiency, anemia, bone lesions). 24 Patients meeting either but not both of these two criteria were also included in the study if they met the additional criteria of having X95% phenotypically aberrant PC in the BM PC compartment (aberrant PC/BM PC) and immunoparesis. 25 The BM samples were collected at the time of entering the study and at disease progression to symptomatic myeloma. Patient characteristics are shown in Supplementary Table 1. In all the BM samples, CD138-positive PC isolation was carried out using the AutoMACs automated separation system (Miltenyi-Biotec, Auburn, CA, USA). Purity was 495% in all SMM cases. The systematic screening for genomic aberrations includes interphase fluorescence in situ hybridization studies for detecting IGH rearrangements (LSI IGH dual-color, break-apart rearrangement probe; Abbott Molecular/Vysis, Des Plaines, IL, USA), 13q (LSI 13, RB1 13q14) and 17p deletions (LSI p53, 17p13.1) (Abbott Molecular/Vysis) as previously described, and 1q gains (ON 1q21/SRD 1p36, Kreatech Diagnostics, Amsterdam, Netherlands). Those SMM samples with IGH translocations were explored for t(11;14)(q13;q32), t(4;14)(p16;q32) and t(14;16)(q32;q23) with the corresponding dual-color, dual-fusion translocation probes from Abbott Molecular/Vysis. The interphase fluorescence in situ hybridization procedure has been described previously in detail. 26 A total of 200 interphase nuclei were analyzed using the scoring criteria recommended by the manufacturer. The cut-off level for the identification of IGH translocations (fusion/break-apart probes) and 1q gains was set at 10% and at 20% for numerical abnormalities, as recommended by the European Myeloma Network fluorescence in situ hybridization workshop. All tests were performed on the SMM sample and positive tests were repeated on the progression to MM sample.
Approximately 100 ng of DNA underwent whole-genome sequencing using 120-bp paired-end reads on a GAIIx (Illumina, Saffron Walden, UK) to a median depth of 44 Â, with 99% of the genome covered at 41 Â and 96%420 Â coverage. From each patient, the non-involved peripheral white blood cells were sequenced as well as BM-derived CD138-selected cells from the HR-SMM diagnosis sample and the sample following progression to MM. Two patients were also sequenced to a higher depth by exome sequencing (see Supplementary Table 2 for metrics). In addition, whole exome sequencing was performed in an identical manner following exome capture using the Agilent SureSelect Human All Exon 50 Mb system on four MGUS, 22 MM (previously published) 27 and two PCL paired tumor/ normal samples (see Supplementary Table 2 Paired reads were aligned to the human genome (GRCh37) using Stampy 28 and BWA, 29 and duplicate reads were removed using Picard. Sequence recalibration, local realignment and single-nucleotide variant (SNV) calling were all undertaken using the GATK. 30 SnpEff was used to functionally annotate all variants. Further filtering of variants and comparisons between samples were performed using code written in R. Variants present in both the peripheral blood and tumor samples were discarded. Only variants sequenced to a minimum depth of 10 Â in both the tumor and matched normal sample, as well as having a minimum genotype score of greater than 50 (representing a 1 in 100 000 error rate) and no more than one variant read in the normal sample were retained. Variants were determined to be unique to a disease stage or present in both stages by comparing the base calls at the location of the SNV in both samples. A high-level overview of the analysis pipeline is given in Supplementary Figure 1 .
Whole-genome copy number was called using a combination of the R package BICseq to perform segmentation of the log ratio of the read depth between matched peripheral blood and tumor samples and the R package CGHcall to produce integer copy calls within the segmented regions. Copy number in exome samples was similarly determined using the R package ExomeCNV.
The proportion of cells containing a variant was estimated using the following equation:
Where p is the proportion of cells containing the variant, C is the integer copy number at that position, r is the number of reads containing the variant and R is the total number of reads. Note that this method assumes that the tumor cell population is free from normal cell contamination and that detected copy number changes are not subclonal.
RESULTS

Mutation characteristics
We performed whole exome sequencing of DNA derived from a series of samples with MGUS (n ¼ 4), MM (n ¼ 22) and PCL (n ¼ 2), as well as four HR-SMM and MM paired samples from the same patients, in order to characterize the changes present in MGUS, HR-SMM, MM and finally in PCL. Tables 5 and 6 ). We therefore show that the number of NS-SNVs increases with disease progression from MGUS to PCL (Figure 1b) . We have previously shown that there is an intraclonal heterogeneity, at the level of SNVs, in presenting myeloma. 27 We used a similar approach to analyze the data generated in this study to determine whether there is clonal heterogeneity present at the early premalignant stages of disease (MGUS and HR-SMM) as well as at the advanced stage of disease (PCL). The kernel density plots in Figure 2 show several distinct peaks indicating a similar level of heterogeneity exists at all stages of disease from MGUS to PCL. This intraclonal heterogeneity at the MGUS stage is consistent with clonal diversity arising early on in the process of myelomagenesis and with clonal competition being an essential requirement from the earliest phases of disease. The rate of transformation from MGUS to MM is slow, which is consistent with the requirement for the acquisition of multiple mutations that are able to deregulate driver genes, but these constitute rare events.
Having shown the presence of intraclonal heterogeneity at each stage of the disease, we were keen to understand how the relationship between subclones changes with the development of clinical symptoms and whether this relationship followed Darwinian principles. In order to accurately determine the changes occurring in the transition from HR-SMM to MM, we analyzed three sets of patients with paired HR-SMM and MM samples taken at least 21 months apart. SNVs were called for each of the genomes sequenced and in the order of 19 000 acquired variants were detected, Supplementary Table 4. Of the total acquired SNVs, 93% (range 91-95%) were detected in both the HR-SMM and MM samples, with 81% (range 64-94%) of the variants being present in less than half of the tumor cells at both stages. Only 3.3% (range 0.3-8.1%) of variants were present in greater than 90% of MM cells. This observation suggests that both HR-SMM and MM contain many subclones at low frequencies, a feature that would be anticipated if disease progression was the result of clonal competition.
After calculating the proportion of cells that contained each variant, by combining base calls and copy number data, it was possible to define the subclonal composition of each disease stage. The relationship between the various subclones was best illustrated when kernel density plots were created for each patient, Figure 3a , and these clearly show changes in clonal composition over time. The same data are displayed as a two-dimensional scatterplot with kernel density estimates represented as a color scale, Figure 3b . In order to identify clusters in these plots, an expectation-maximization based model was used to group the data, Figure 3c (and Supplementary  Figure 2) . Typically, around six clusters were identified per sample pair, and although these variant clusters do not directly represent clones, they can be used to demonstrate clonal evolution over time.
One paired set of samples was sourced from a patient who was treated with lenalidomide and dexamethasone and clearly demonstrates that chemotherapy results in a reduction in clonal complexity, Figures 3d-f. For example, cluster A was dominant at the HR-SMM stage, with mutations present in 80-100% of cells, but after treatment it has decreased to 0-20% of cells. Some clusters were largely unaffected by the treatment (clusters B, E, F, H and I that stay around the diagonal). Conversely, cluster D has gone from 0 to 20% of cells at HR-SMM and risen to 40-60% at progression to MM, perhaps due to therapy resistance. Acquired genetic change in the progression from HR-SMM to MM Having shown changes in intraclonal composition during disease progression, we sought to define the genetic changes mediating the differences in subclonal behavior facilitating the growth and survival advantage for the clone mediating disease progression.
There were on average 433 additional novel and unique mutations (range 341-517) gained per sample during the transition from HR-SMM to symptomatic MM, few (mean 2.3) were present within coding regions and only one was NS, Table 1 . The one case with the acquired NS-mutation was characterized by the acquisition of a novel acquired stop mutation at amino-acid position 31 (c.G92A, p.W31*) in RUNX2, located on chromosome 6, which has features of an important driver mutation and could mediate the changes in biology that could cause the transition. There was no copy number change at this locus, indicating that haplo-insufficiency may be a mechanism at work. Understanding the rate of mutation acquisition is important, and as we know the time to progression for the studied patients we used the number of variants unique to each HR-SMM and MM sample to calculate the rate at which new mutations were gained and existing mutations lost, or at least became undetectable at the level of sensitivity of the test used. The mean across the three cases was 19 mutations gained and 36 mutations lost per month.
Importantly, from a mechanistic perspective it seems that copy number change occurs relatively early in these cases, as using fluorescence in situ hybridization, at a macroscopic level, we could not see significant copy number change during the transition, a feature that was recapitulated when the sequencing data were used to generate copy number data across the genome, Supplementary Figure 3 . These data indicate that in these three cases, the acquisition of copy number abnormalities does not facilitate the transformation between the two disease stages and was a feature of earlier stages of the disease.
Progression could also be mediated by chromosomal rearrangement, and we used the data generated here to describe a number of translocations, finding events that exist in both the HR-SMM and MM samples, as well as those that are either gained or lost in the HR-SMM to MM transition, Figure 4 and Supplementary Table 7 . Translocations acquired in the transition from HR-SMM to symptomatic MM could readily mediate disease progression, and we describe a number of these. These include a translocation in patient two, involving BRCA2 that was disrupted by a t (13;21) . Also, in patient five, several translocations involving UNC5D were seen which was notable for its complexity, involving three separate translocation events.
The limited number of novel NS-SNVs, indels and translocations, which characterize the transformed MM samples indicates that by the time a case has evolved to the HR-SMM stage the majority, if not all, of the exonic genetic diversity necessary to give rise to an aggressive clinical state is already present. We show that 1732 mutations were acquired in the MM samples, of which only one was NS. However, there is a substantial intronic diversity, the significance of which has not previously been demonstrated.
DISCUSSION
It has been thought that the acquisition of mutations over time leads to the progression of cancer from an essentially benign to clinically aggressive behavioral states. We have used massively parallel sequencing to study the multistep progression from a normal PC to one that has leukemic properties, with the aim of describing the genetic and subclonal events which characterize disease progression. We show that the number of NS mutations defining cases of symptomatic MM is B23, a number intermediate between simple cancers, such as acute myeloid leukemia, 31 and the more complex solid cancers. 32 On the basis of the data generated here, and single-cell data analyzed previously, we suggest that there are approximately six predominant clones with much greater complexity existing below the sensitivity of the sequencing approach we have used. We go on to show that MGUS has fewer NS mutations than the later stages of disease, including HR-SMM, MM and PCL. However, when we look at the nature and sites of mutation present at each disease stage, they do not differ, an observation that is consistent with the same molecular mechanisms being active throughout the course of the disease.
To date, the genomes of the premalignant stages of MM have not been sequenced and compared with those of symptomatic MM or PCL. Here we demonstrate that there is an increase in the number of NS mutations as the disease progresses from MGUS to HR-SMM and MM. This is in line with previous copy number abnormality data which indicate that the genetic complexity of the disease increases toward MM. [14] [15] [16] [17] MGUS is known to take 425 years to progress to symptomatic MM, whereas SMM takes o5 years to progress. In this context, it is interesting to note that the MGUS samples are very much less complex compared with symptomatic MM, having approximately half the number of NS mutations, whereas the HR-SMM samples have an equal number of mutations compared with symptomatic MM. We demonstrate clear evidence of subclonal heterogeneity in all stages of disease from MGUS to PCL, which is an essential substrate for Darwinian type evolution, suggesting that disease progression is mediated via competition between subclones and outgrowth of the fittest. In this report, for the first time, we demonstrate that intraclonal heterogeneity is present in MGUS, the earliest clinically recognizable stage of MM, and that it is also present in the later stages of the disease, including HR-SMM and PCL. These observations are consistent with intraclonal heterogeneity being a critical and consistent feature of both the early and late stages of myeloma. It is also consistent with clonal competition being active from the earliest phases of disease until its highly aggressive late stages and provides direct evidence to support the hypothesis that Darwinian evolution mediates progression through the multiple steps of the disease model of MM. The development of PCL via this complex evolutionary process characterized by extreme deregulation of the behavior of the normal cellular counterpart is consistent with the poor results of treatment associated with this stage of the disease. This situation can be contrasted with the results of the treatment of de-novo acute leukemia which can be cured probably because of the significantly less number of genetic hits required to deregulate a hematopoietic stem cell.
In order to directly demonstrate the subclonal relationships underlying the transitions between the disease phases of myeloma, we paid particular attention to the HR-SMM/MM transition using serial samples from the same individuals. This is a critical transition, where an essentially benign state, that it not treated, undergoes a change that results in clinical symptoms consistent with clonally destructive behavior and the development of end-organ damage. Using kernel plot analysis of these paired samples, we can see changes in clonal composition, mediated via the expansion of specific subclones, associated with the transition, an observation that is consistent with previous observations concerning the clonal expansion of genetically abnormal cells.
14 Further, looking at the clonal composition of the paired samples, we show that the transformation of HR-SMM to MM is not the result of the outgrowth of a single clone but results from the outgrowth of a number of subclones, already present in the HR-SMM sample. It seems that, in MM, up to six clones change during the HR-SMM-MM transition, which is more than that has been suggested previously in pediatric acute lymphoblastic leukemia, 23 reflecting the increased genetic and subclonal heterogeneity seen in MM compared with this rather simple cancer model.
The question then arises as to the nature of the molecular mechanisms driving the subclonal changes. At the HR-SMM time point, we show that the majority of the NS exonic changes are already present and that only a few additional changes are seen following transformation. We describe one case, patient two, in which an acquired NS-SNV variant in RUNX2 is seen following progression to MM, which could plausibly drive the expansion of the clone carrying it. Consistent with this, RUNX2 is expressed in myeloma cells and regulates osteopontin, a multifunctional bone matrix glycoprotein that is involved in angiogenesis, cell survival and proliferation. 33, 34 RUNX2 mutations are also seen in a range of cancers with three stop mutations, 17 NS and six synonymous mutations having been described. 35 These features are consistent with inactivating mutations in RUNX2 having a credible role in the progression of myeloma.
We also describe a number of translocations, three of which are only present in the MM sample. Of interest, also in patient two, we describe a translocation disrupting one allele of BRCA2, which could mediate clonal behavior. The other interesting feature is several translocations into UNC5D, in patient five, which is very complex and could be an interesting mechanism mediating disease progression and is a known feature of myeloma. 36, 37 UNC5D has been implicated in predisposition to colon cancer and is mutated in 9% of diffuse large B-cell lymphomas as well as being involved in translocations in breast cancer. 35, 38, 39 It has a role as a netrin-1 receptor, is transcriptionally controlled by p53 and induces apoptosis, thus making it a good candidate for tumor progression in myeloma. 40 Apart from inactivating mutations in RUNX2 and acquired translocations into BRCA2 and UNC5D, we could not identify any truly acquired genetic abnormalities between the paired samples despite thoroughly checking for coding SNVs, indels and copy number abnormalities. Having exhaustively searched for acquired mutational change to explain the transition and having found only limited numbers of potential molecular drivers to explain the development of clinical symptoms and how disease progression could be mediated, alternative explanations should be considered. There are a number of non-mutational changes that could mediate the transition including epigenetic changes, which we have not looked for in this study but have been described previously. 9, 10 Alternatively, on the basis of the changes in subclonal composition, as a consequence of an increase in tumor bulk there is a threshold effect above which the MM cells modify the microenvironment, such that they favor increased proliferation and expansion of a subclone best suited to that environment, the net consequence of which is subclonal expansion and the development of end-organ damage.
When these observations based on the experimental characterization of the multiple disease phases of myeloma and the transition of HR-SMM to MM in particular are considered, it seems likely that HR-SMM is not a distinct disease entity but is rather a transition state between MGUS and MM, where the subclonal structure is evolving. MGUS is a benign clinical state which is stable with no clinical symptoms that contrasts with presenting myeloma when tumor bulk has reached a critical threshold and clinical damage has developed. The in-between state, SMM, seems to represent a phase characterized by ongoing competition between subclones with the rate of transformation depending upon the nature and rate of mutations that drive the process.
We present a coherent hypothesis based on the data we find in myeloma tumor sequencing data. In this hypothesis, adaptation is driven by genetic variation in the tumor cells. At presentation the only selective pressures are those that occur naturally and would involve competition for the myeloma cell niche in the BM and the avoidance of selective pressures exerted by the immune system. Once treatment has been initiated, the selective pressures change and possibly the evolution of the tumor is enhanced by exposure to treatment.
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